New Launch4 Jul 2025, 03:15 pm
Lupin Launches Ipratropium Bromide Nasal Solution in the US
AI Summary
Global pharma major Lupin Limited has announced the launch of Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. The product is bioequivalent to Atrovent® Nasal Spray of Boehringer Ingelheim Pharmaceuticals, Inc. The 0.03% solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. The 0.06% solution is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. The RLD Atrovent® had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).
Key Highlights
- Lupin launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States.
- The product is bioequivalent to Atrovent® Nasal Spray of Boehringer Ingelheim Pharmaceuticals, Inc.
- The 0.03% solution is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older.
- The 0.06% solution is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.
- The RLD Atrovent® had estimated annual sales of USD 63 million in the U.S. (IQVIA MAT May 2025).